BizToc

[ad_1]

GSK PLC said Friday that a Phase 3 trial for its Jemperli treatment for advanced or recurrent endometrial cancer met its primary endpoint, showing meaningful improvement in progression-free survival. The pharmaceutical giant GSK, The trial showed a statistically significant and clinically…

#gskplc #theeuropeanmedicinesagency #acommitteeformedicinalproductsforh #gsk #joehoppe